nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Generalised oedema—Cisplatin—bone cancer	0.0314	0.0314	CcSEcCtD
Gadoteridol—Neck stiffness—Methotrexate—bone cancer	0.0215	0.0215	CcSEcCtD
Gadoteridol—Nuchal rigidity—Methotrexate—bone cancer	0.0198	0.0198	CcSEcCtD
Gadoteridol—Pain—Carboplatin—bone cancer	0.0194	0.0194	CcSEcCtD
Gadoteridol—Wheezing—Cisplatin—bone cancer	0.0181	0.0181	CcSEcCtD
Gadoteridol—Body temperature increased—Carboplatin—bone cancer	0.018	0.018	CcSEcCtD
Gadoteridol—Fluid retention—Cisplatin—bone cancer	0.0177	0.0177	CcSEcCtD
Gadoteridol—Generalised oedema—Epirubicin—bone cancer	0.0161	0.0161	CcSEcCtD
Gadoteridol—Generalised oedema—Doxorubicin—bone cancer	0.0149	0.0149	CcSEcCtD
Gadoteridol—Cyanosis—Methotrexate—bone cancer	0.0145	0.0145	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Cisplatin—bone cancer	0.014	0.014	CcSEcCtD
Gadoteridol—Stupor—Methotrexate—bone cancer	0.0137	0.0137	CcSEcCtD
Gadoteridol—Face oedema—Cisplatin—bone cancer	0.0131	0.0131	CcSEcCtD
Gadoteridol—Gingivitis—Methotrexate—bone cancer	0.0131	0.0131	CcSEcCtD
Gadoteridol—Gingivitis—Epirubicin—bone cancer	0.0122	0.0122	CcSEcCtD
Gadoteridol—Apnoea—Methotrexate—bone cancer	0.0121	0.0121	CcSEcCtD
Gadoteridol—Injection site pain—Epirubicin—bone cancer	0.0118	0.0118	CcSEcCtD
Gadoteridol—Musculoskeletal stiffness—Methotrexate—bone cancer	0.0114	0.0114	CcSEcCtD
Gadoteridol—Gingivitis—Doxorubicin—bone cancer	0.0113	0.0113	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Epirubicin—bone cancer	0.0109	0.0109	CcSEcCtD
Gadoteridol—Injection site pain—Doxorubicin—bone cancer	0.0109	0.0109	CcSEcCtD
Gadoteridol—Lacrimation increased—Epirubicin—bone cancer	0.0104	0.0104	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Doxorubicin—bone cancer	0.0101	0.0101	CcSEcCtD
Gadoteridol—Depressed level of consciousness—Methotrexate—bone cancer	0.0099	0.0099	CcSEcCtD
Gadoteridol—Lacrimation increased—Doxorubicin—bone cancer	0.00963	0.00963	CcSEcCtD
Gadoteridol—Bradycardia—Cisplatin—bone cancer	0.00955	0.00955	CcSEcCtD
Gadoteridol—Injection site reaction—Epirubicin—bone cancer	0.00954	0.00954	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Epirubicin—bone cancer	0.00932	0.00932	CcSEcCtD
Gadoteridol—Fluid retention—Epirubicin—bone cancer	0.00911	0.00911	CcSEcCtD
Gadoteridol—Injection site reaction—Doxorubicin—bone cancer	0.00883	0.00883	CcSEcCtD
Gadoteridol—Tinnitus—Cisplatin—bone cancer	0.00875	0.00875	CcSEcCtD
Gadoteridol—Rash maculo-papular—Epirubicin—bone cancer	0.00872	0.00872	CcSEcCtD
Gadoteridol—Flushing—Cisplatin—bone cancer	0.00871	0.00871	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Doxorubicin—bone cancer	0.00862	0.00862	CcSEcCtD
Gadoteridol—Fluid retention—Doxorubicin—bone cancer	0.00843	0.00843	CcSEcCtD
Gadoteridol—Erythema—Cisplatin—bone cancer	0.00817	0.00817	CcSEcCtD
Gadoteridol—Rash maculo-papular—Doxorubicin—bone cancer	0.00807	0.00807	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Methotrexate—bone cancer	0.00769	0.00769	CcSEcCtD
Gadoteridol—Tremor—Cisplatin—bone cancer	0.00765	0.00765	CcSEcCtD
Gadoteridol—Ill-defined disorder—Cisplatin—bone cancer	0.00758	0.00758	CcSEcCtD
Gadoteridol—Malaise—Cisplatin—bone cancer	0.00737	0.00737	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Epirubicin—bone cancer	0.0072	0.0072	CcSEcCtD
Gadoteridol—Convulsion—Cisplatin—bone cancer	0.00708	0.00708	CcSEcCtD
Gadoteridol—Anxiety—Cisplatin—bone cancer	0.00693	0.00693	CcSEcCtD
Gadoteridol—Discomfort—Cisplatin—bone cancer	0.00687	0.00687	CcSEcCtD
Gadoteridol—Face oedema—Epirubicin—bone cancer	0.00672	0.00672	CcSEcCtD
Gadoteridol—Anaphylactic shock—Cisplatin—bone cancer	0.00667	0.00667	CcSEcCtD
Gadoteridol—Oedema—Cisplatin—bone cancer	0.00667	0.00667	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Doxorubicin—bone cancer	0.00666	0.00666	CcSEcCtD
Gadoteridol—Cardiac arrest—Epirubicin—bone cancer	0.00662	0.00662	CcSEcCtD
Gadoteridol—Hyperhidrosis—Cisplatin—bone cancer	0.00644	0.00644	CcSEcCtD
Gadoteridol—Hypotension—Cisplatin—bone cancer	0.00623	0.00623	CcSEcCtD
Gadoteridol—Face oedema—Doxorubicin—bone cancer	0.00622	0.00622	CcSEcCtD
Gadoteridol—Cardiac arrest—Doxorubicin—bone cancer	0.00613	0.00613	CcSEcCtD
Gadoteridol—Dysphagia—Epirubicin—bone cancer	0.00602	0.00602	CcSEcCtD
Gadoteridol—Paraesthesia—Cisplatin—bone cancer	0.00599	0.00599	CcSEcCtD
Gadoteridol—Dyspnoea—Cisplatin—bone cancer	0.00594	0.00594	CcSEcCtD
Gadoteridol—Pain—Cisplatin—bone cancer	0.0057	0.0057	CcSEcCtD
Gadoteridol—Dysphagia—Doxorubicin—bone cancer	0.00557	0.00557	CcSEcCtD
Gadoteridol—Sweating—Methotrexate—bone cancer	0.0055	0.0055	CcSEcCtD
Gadoteridol—Feeling abnormal—Cisplatin—bone cancer	0.00549	0.00549	CcSEcCtD
Gadoteridol—Body temperature increased—Cisplatin—bone cancer	0.00527	0.00527	CcSEcCtD
Gadoteridol—Sweating—Epirubicin—bone cancer	0.00515	0.00515	CcSEcCtD
Gadoteridol—Hypersensitivity—Cisplatin—bone cancer	0.00491	0.00491	CcSEcCtD
Gadoteridol—Bradycardia—Epirubicin—bone cancer	0.00491	0.00491	CcSEcCtD
Gadoteridol—Rhinitis—Epirubicin—bone cancer	0.00483	0.00483	CcSEcCtD
Gadoteridol—Tinnitus—Methotrexate—bone cancer	0.0048	0.0048	CcSEcCtD
Gadoteridol—Sweating—Doxorubicin—bone cancer	0.00476	0.00476	CcSEcCtD
Gadoteridol—Diarrhoea—Cisplatin—bone cancer	0.00456	0.00456	CcSEcCtD
Gadoteridol—Bradycardia—Doxorubicin—bone cancer	0.00454	0.00454	CcSEcCtD
Gadoteridol—Tinnitus—Epirubicin—bone cancer	0.00449	0.00449	CcSEcCtD
Gadoteridol—Erythema—Methotrexate—bone cancer	0.00448	0.00448	CcSEcCtD
Gadoteridol—Flushing—Epirubicin—bone cancer	0.00447	0.00447	CcSEcCtD
Gadoteridol—Rhinitis—Doxorubicin—bone cancer	0.00447	0.00447	CcSEcCtD
Gadoteridol—Dysgeusia—Methotrexate—bone cancer	0.00439	0.00439	CcSEcCtD
Gadoteridol—Vomiting—Cisplatin—bone cancer	0.00424	0.00424	CcSEcCtD
Gadoteridol—Rash—Cisplatin—bone cancer	0.0042	0.0042	CcSEcCtD
Gadoteridol—Dermatitis—Cisplatin—bone cancer	0.0042	0.0042	CcSEcCtD
Gadoteridol—Erythema—Epirubicin—bone cancer	0.00419	0.00419	CcSEcCtD
Gadoteridol—Ill-defined disorder—Methotrexate—bone cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Tinnitus—Doxorubicin—bone cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Flushing—Doxorubicin—bone cancer	0.00414	0.00414	CcSEcCtD
Gadoteridol—Dysgeusia—Epirubicin—bone cancer	0.00411	0.00411	CcSEcCtD
Gadoteridol—Malaise—Methotrexate—bone cancer	0.00404	0.00404	CcSEcCtD
Gadoteridol—Nausea—Cisplatin—bone cancer	0.00396	0.00396	CcSEcCtD
Gadoteridol—Cough—Methotrexate—bone cancer	0.00391	0.00391	CcSEcCtD
Gadoteridol—Ill-defined disorder—Epirubicin—bone cancer	0.00389	0.00389	CcSEcCtD
Gadoteridol—Convulsion—Methotrexate—bone cancer	0.00388	0.00388	CcSEcCtD
Gadoteridol—Erythema—Doxorubicin—bone cancer	0.00388	0.00388	CcSEcCtD
Gadoteridol—Chest pain—Methotrexate—bone cancer	0.00382	0.00382	CcSEcCtD
Gadoteridol—Dysgeusia—Doxorubicin—bone cancer	0.0038	0.0038	CcSEcCtD
Gadoteridol—Malaise—Epirubicin—bone cancer	0.00378	0.00378	CcSEcCtD
Gadoteridol—Discomfort—Methotrexate—bone cancer	0.00377	0.00377	CcSEcCtD
Gadoteridol—Syncope—Epirubicin—bone cancer	0.00376	0.00376	CcSEcCtD
Gadoteridol—Loss of consciousness—Epirubicin—bone cancer	0.00369	0.00369	CcSEcCtD
Gadoteridol—Cough—Epirubicin—bone cancer	0.00366	0.00366	CcSEcCtD
Gadoteridol—Anaphylactic shock—Methotrexate—bone cancer	0.00366	0.00366	CcSEcCtD
Gadoteridol—Convulsion—Epirubicin—bone cancer	0.00363	0.00363	CcSEcCtD
Gadoteridol—Hypertension—Epirubicin—bone cancer	0.00362	0.00362	CcSEcCtD
Gadoteridol—Ill-defined disorder—Doxorubicin—bone cancer	0.0036	0.0036	CcSEcCtD
Gadoteridol—Chest pain—Epirubicin—bone cancer	0.00357	0.00357	CcSEcCtD
Gadoteridol—Anxiety—Epirubicin—bone cancer	0.00356	0.00356	CcSEcCtD
Gadoteridol—Hyperhidrosis—Methotrexate—bone cancer	0.00354	0.00354	CcSEcCtD
Gadoteridol—Discomfort—Epirubicin—bone cancer	0.00353	0.00353	CcSEcCtD
Gadoteridol—Malaise—Doxorubicin—bone cancer	0.0035	0.0035	CcSEcCtD
Gadoteridol—Dry mouth—Epirubicin—bone cancer	0.00349	0.00349	CcSEcCtD
Gadoteridol—Syncope—Doxorubicin—bone cancer	0.00348	0.00348	CcSEcCtD
Gadoteridol—Oedema—Epirubicin—bone cancer	0.00342	0.00342	CcSEcCtD
Gadoteridol—Anaphylactic shock—Epirubicin—bone cancer	0.00342	0.00342	CcSEcCtD
Gadoteridol—Hypotension—Methotrexate—bone cancer	0.00342	0.00342	CcSEcCtD
Gadoteridol—Loss of consciousness—Doxorubicin—bone cancer	0.00341	0.00341	CcSEcCtD
Gadoteridol—Cough—Doxorubicin—bone cancer	0.00339	0.00339	CcSEcCtD
Gadoteridol—Shock—Epirubicin—bone cancer	0.00337	0.00337	CcSEcCtD
Gadoteridol—Convulsion—Doxorubicin—bone cancer	0.00336	0.00336	CcSEcCtD
Gadoteridol—Hypertension—Doxorubicin—bone cancer	0.00335	0.00335	CcSEcCtD
Gadoteridol—Hyperhidrosis—Epirubicin—bone cancer	0.00331	0.00331	CcSEcCtD
Gadoteridol—Chest pain—Doxorubicin—bone cancer	0.0033	0.0033	CcSEcCtD
Gadoteridol—Anxiety—Doxorubicin—bone cancer	0.00329	0.00329	CcSEcCtD
Gadoteridol—Paraesthesia—Methotrexate—bone cancer	0.00328	0.00328	CcSEcCtD
Gadoteridol—Discomfort—Doxorubicin—bone cancer	0.00326	0.00326	CcSEcCtD
Gadoteridol—Dyspnoea—Methotrexate—bone cancer	0.00326	0.00326	CcSEcCtD
Gadoteridol—Dry mouth—Doxorubicin—bone cancer	0.00323	0.00323	CcSEcCtD
Gadoteridol—Hypotension—Epirubicin—bone cancer	0.0032	0.0032	CcSEcCtD
Gadoteridol—Oedema—Doxorubicin—bone cancer	0.00317	0.00317	CcSEcCtD
Gadoteridol—Anaphylactic shock—Doxorubicin—bone cancer	0.00317	0.00317	CcSEcCtD
Gadoteridol—Pain—Methotrexate—bone cancer	0.00313	0.00313	CcSEcCtD
Gadoteridol—Shock—Doxorubicin—bone cancer	0.00312	0.00312	CcSEcCtD
Gadoteridol—Paraesthesia—Epirubicin—bone cancer	0.00307	0.00307	CcSEcCtD
Gadoteridol—Hyperhidrosis—Doxorubicin—bone cancer	0.00306	0.00306	CcSEcCtD
Gadoteridol—Dyspnoea—Epirubicin—bone cancer	0.00305	0.00305	CcSEcCtD
Gadoteridol—Feeling abnormal—Methotrexate—bone cancer	0.00301	0.00301	CcSEcCtD
Gadoteridol—Hypotension—Doxorubicin—bone cancer	0.00296	0.00296	CcSEcCtD
Gadoteridol—Pain—Epirubicin—bone cancer	0.00293	0.00293	CcSEcCtD
Gadoteridol—Urticaria—Methotrexate—bone cancer	0.00291	0.00291	CcSEcCtD
Gadoteridol—Body temperature increased—Methotrexate—bone cancer	0.00289	0.00289	CcSEcCtD
Gadoteridol—Abdominal pain—Methotrexate—bone cancer	0.00289	0.00289	CcSEcCtD
Gadoteridol—Paraesthesia—Doxorubicin—bone cancer	0.00284	0.00284	CcSEcCtD
Gadoteridol—Dyspnoea—Doxorubicin—bone cancer	0.00282	0.00282	CcSEcCtD
Gadoteridol—Feeling abnormal—Epirubicin—bone cancer	0.00282	0.00282	CcSEcCtD
Gadoteridol—Urticaria—Epirubicin—bone cancer	0.00272	0.00272	CcSEcCtD
Gadoteridol—Pain—Doxorubicin—bone cancer	0.00271	0.00271	CcSEcCtD
Gadoteridol—Abdominal pain—Epirubicin—bone cancer	0.00271	0.00271	CcSEcCtD
Gadoteridol—Body temperature increased—Epirubicin—bone cancer	0.00271	0.00271	CcSEcCtD
Gadoteridol—Hypersensitivity—Methotrexate—bone cancer	0.0027	0.0027	CcSEcCtD
Gadoteridol—Feeling abnormal—Doxorubicin—bone cancer	0.00261	0.00261	CcSEcCtD
Gadoteridol—Pruritus—Methotrexate—bone cancer	0.00259	0.00259	CcSEcCtD
Gadoteridol—Hypersensitivity—Epirubicin—bone cancer	0.00252	0.00252	CcSEcCtD
Gadoteridol—Urticaria—Doxorubicin—bone cancer	0.00252	0.00252	CcSEcCtD
Gadoteridol—Body temperature increased—Doxorubicin—bone cancer	0.0025	0.0025	CcSEcCtD
Gadoteridol—Abdominal pain—Doxorubicin—bone cancer	0.0025	0.0025	CcSEcCtD
Gadoteridol—Diarrhoea—Methotrexate—bone cancer	0.0025	0.0025	CcSEcCtD
Gadoteridol—Pruritus—Epirubicin—bone cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Dizziness—Methotrexate—bone cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Diarrhoea—Epirubicin—bone cancer	0.00234	0.00234	CcSEcCtD
Gadoteridol—Hypersensitivity—Doxorubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Gadoteridol—Vomiting—Methotrexate—bone cancer	0.00233	0.00233	CcSEcCtD
Gadoteridol—Rash—Methotrexate—bone cancer	0.00231	0.00231	CcSEcCtD
Gadoteridol—Dermatitis—Methotrexate—bone cancer	0.0023	0.0023	CcSEcCtD
Gadoteridol—Headache—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Gadoteridol—Dizziness—Epirubicin—bone cancer	0.00226	0.00226	CcSEcCtD
Gadoteridol—Pruritus—Doxorubicin—bone cancer	0.00224	0.00224	CcSEcCtD
Gadoteridol—Vomiting—Epirubicin—bone cancer	0.00218	0.00218	CcSEcCtD
Gadoteridol—Nausea—Methotrexate—bone cancer	0.00217	0.00217	CcSEcCtD
Gadoteridol—Diarrhoea—Doxorubicin—bone cancer	0.00217	0.00217	CcSEcCtD
Gadoteridol—Rash—Epirubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Dermatitis—Epirubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Headache—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Gadoteridol—Dizziness—Doxorubicin—bone cancer	0.00209	0.00209	CcSEcCtD
Gadoteridol—Nausea—Epirubicin—bone cancer	0.00203	0.00203	CcSEcCtD
Gadoteridol—Vomiting—Doxorubicin—bone cancer	0.00201	0.00201	CcSEcCtD
Gadoteridol—Rash—Doxorubicin—bone cancer	0.002	0.002	CcSEcCtD
Gadoteridol—Dermatitis—Doxorubicin—bone cancer	0.002	0.002	CcSEcCtD
Gadoteridol—Headache—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Gadoteridol—Nausea—Doxorubicin—bone cancer	0.00188	0.00188	CcSEcCtD
